Sign in
GUTS Stock Price, Chart, Stats & News
Fractyl Health, Inc.
Save
Fractyl Health, Inc. (GUTS) does not currently pay a dividend.
77.04M
Market cap
–
Current P/E
–
Forward P/E
GUTS chart
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | – |
ROA | -116.11% |
ROE | 10146.05% |
D/E | 6.52x |
Interest coverage ratio | – |
GUTS valuation
P/E | – |
P/S | – |
P/B | 3.60x |
P/CF | -0.38x |
P/FCF | -0.36x |
P/OCF | -0.38x |
PEG | 0.08x |
EV multiple | -0.44x |
About
Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. It develops Rejuva, a novel adeno-associated virus delivered pancreatic gene therapy platform that is designed to enable long-term remission of T2D and obesity by durably altering metabolic hormone function in the pancreatic islet cells of patients.
Similar securities
Based on sector and market capitalization
Report issue